List of Excipients in Branded Drug OCTOCAINE 100

« Back to Dashboard

Generic Drugs Containing OCTOCAINE 100

Company	Ingredient	NDC	Excipient
Septodont	lidocaine hydrochloride and epinephrine bitartrate	0362-9023	EDETATE DISODIUM
Septodont	lidocaine hydrochloride and epinephrine bitartrate	0362-9023	POTASSIUM METABISULFITE
Septodont	lidocaine hydrochloride and epinephrine bitartrate	0362-9023	SODIUM CHLORIDE
Septodont	lidocaine hydrochloride and epinephrine bitartrate	0362-9023	SODIUM HYDROXIDE
Septodont	lidocaine hydrochloride and epinephrine bitartrate	0362-9023	WATER

What are the Most Frequently-Used Excipients in OCTOCAINE 100?

# Of NDCs	Excipient
1	EDETATE DISODIUM
1	POTASSIUM METABISULFITE
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Octocaine 100 Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Octocaine 100 is a dental local anesthetic injection containing lidocaine hydrochloride 2% with epinephrine 1:100,000. Its commercial value is driven less by active-ingredient differentiation than by excipient control, container-closure performance, supply reliability, preservative positioning, and dental-practice economics. The strongest opportunities are sulfite-reduced or sulfite-free presentations, improved stability systems, low-waste packaging, and differentiated delivery formats.

What is Octocaine 100 and which excipients does it contain?

Octocaine 100 contains 20 mg/mL lidocaine hydrochloride and 0.01 mg/mL epinephrine, equivalent to a 1:100,000 epinephrine concentration. The product is supplied as a sterile dental injection in cartridges or other dental delivery containers, depending on market and presentation.[1]

The principal excipient system generally includes:

Component	Function
Sodium chloride	Tonicity adjustment
Sodium metabisulfite	Antioxidant for epinephrine stabilization
Water for injection	Sterile vehicle
Hydrochloric acid and/or sodium hydroxide	pH adjustment

The formulation is chemically constrained. Lidocaine is relatively stable in aqueous solution, but epinephrine is susceptible to oxidation. The antioxidant system, oxygen exposure, pH, headspace, light transmission, elastomer compatibility, and sterilization process collectively determine shelf life.

The formulation should be assessed as a combination product of active ingredients, excipients, and packaging. Changing sodium metabisulfite concentration, pH, oxygen content, cartridge material, or closure components can alter epinephrine potency, impurity formation, color, sterility assurance, and extractables profiles.

How does the Octocaine 100 excipient system work?

Sodium metabisulfite and epinephrine stability

Sodium metabisulfite is used to limit oxidative degradation of epinephrine. Without an effective antioxidant system, epinephrine can form oxidation products, with visible discoloration often providing an early indication of chemical instability.

The commercial tradeoff is that sulfites can cause hypersensitivity reactions in susceptible patients, particularly individuals with asthma. The presence of sulfite does not make the product unsuitable for dental use, but it creates a product-positioning limitation and a potential target for reformulation.

A reformulation must demonstrate:

• Epinephrine assay retention through shelf life
• Control of oxidation-related impurities
• Acceptable color and clarity
• Sterility and container-closure integrity
• Compatibility with dental cartridge components
• Consistent dose delivery through the dental syringe
• Acceptable local tolerability

Sodium chloride and tonicity

Sodium chloride helps bring the injection closer to physiological tonicity. Tonicity affects injection comfort and local tissue tolerability. An excipient strategy that reduces sodium chloride without introducing another tonicity agent could improve formulation simplicity, but the resulting osmolality and injection-site performance must be validated.

pH adjustment

Lidocaine-epinephrine injections are typically acidic because acidity improves epinephrine stability. Acidic solutions can produce more injection discomfort than buffered formulations. A buffered version could have a commercial advantage if it reduces onset delay or injection pain, but buffering can accelerate epinephrine degradation.

This creates a central formulation tradeoff:

Formulation objective	Likely technical effect
Lower pH	Better epinephrine stability, potentially greater injection discomfort
Higher pH	Potentially faster anesthetic onset and less discomfort, greater oxidation risk
Strong antioxidant system	Better epinephrine protection, greater sulfite exposure
Low-sulfite system	Improved hypersensitivity positioning, greater stability burden
Oxygen-reduced filling	Lower oxidation risk, higher manufacturing complexity

What excipient opportunities exist for Octocaine 100?

Sulfite-free or sulfite-reduced formulations

The most commercially visible opportunity is a formulation that maintains epinephrine stability with reduced or no sulfite. Potential approaches include:

• Oxygen-minimized compounding and filling
• Nitrogen or inert-gas headspace control
• Low-permeability cartridge materials
• Improved light protection
• Alternative antioxidants
• Chelating agents to reduce metal-catalyzed oxidation
• Optimized pH and buffer capacity
• Combination control of oxygen, metals, light, and temperature

A sulfite-free product would need to demonstrate that its impurity profile remains acceptable over the full labeled shelf life. The challenge is not simply replacing sodium metabisulfite. Epinephrine degradation can be affected by trace metals, dissolved oxygen, rubber closures, glass surface chemistry, and manufacturing equipment.

Buffered dental anesthetic

A buffered lidocaine-epinephrine injection could target reduced injection pain and faster clinical onset. Sodium bicarbonate is the most familiar buffering concept for local anesthetics, but its use with epinephrine requires careful control of pH, carbon dioxide generation, precipitation risk, and stability.

A commercial product could use:

• A ready-to-use buffered formulation
• A dual-chamber cartridge
• A point-of-use mixing system
• A buffered lidocaine presentation without epinephrine
• A buffered epinephrine-containing formulation with a tightly controlled pH range

Ready-to-use buffering would have the strongest convenience advantage. Dual-chamber systems could separate unstable components until administration, but they would carry higher device, manufacturing, and regulatory costs.

Preservative-free and single-dose positioning

Dental cartridges are generally intended for single-patient or single-use administration. The absence of antimicrobial preservatives can be positioned as a quality and tolerability advantage where the container system supports it.

Commercial claims must distinguish between:

• Preservative-free
• Sulfite-free
• Single-dose
• Single-use
• Latex-free
• Free of antimicrobial preservatives

These claims are not interchangeable. Sodium metabisulfite is an antioxidant, not an antimicrobial preservative. A product can be preservative-free while still containing a sulfite antioxidant.

Packaging as an excipient-enabling strategy

Packaging is a major determinant of formulation performance. Opportunities include:

• Low-oxygen glass cartridges
• Polymer cartridges with reduced oxygen transmission
• Improved plunger and diaphragm elastomers
• Light-protective secondary packaging
• Reduced extractables and leachables
• More consistent cartridge dimensions
• Unit-dose packaging that reduces clinical waste

The cartridge should be evaluated for epinephrine adsorption, pH drift, tungsten or metal contamination, rubber compound compatibility, and particulate generation. A superior container-closure system may support a longer shelf life or lower antioxidant loading without changing the active ingredients.

What commercial opportunities exist for Octocaine 100?

Premium sulfite-reduced dental anesthetic

A reduced-sulfite product could target dental practices that encounter patients with sulfite sensitivity or asthma-related concerns. The commercial opportunity is likely niche rather than mass-market because lidocaine-epinephrine products are established, price-sensitive products.

A premium product would need a clear operational benefit, such as:

• Lower adverse-reaction concern
• Equivalent anesthetic performance
• Stable supply
• Comparable cartridge compatibility
• No additional chairside preparation
• Competitive reimbursement or acquisition economics

Private-label and contract-manufacturing opportunities

Dental distributors and group purchasing organizations may seek private-label versions of lidocaine-epinephrine cartridges. The differentiation would come from:

• Cartridge size
• Needle compatibility
• Packaging configurations
• Supply continuity
• Distributor exclusivity
• Regional registration support
• Secondary packaging and branding

The active formulation is mature, so contract-manufacturing value depends on validated sterile filling capacity, cartridge assembly, inspection, and regulatory documentation.

Reduced-waste packaging

Dental offices discard partially used cartridges and packaging because of infection-control requirements. Packaging opportunities include:

• Smaller cartons for low-volume practices
• High-count cartons for large dental groups
• Better carton organization
• Tamper-evident unit packaging
• Recyclable secondary packaging
• Improved cartridge break resistance

Packaging changes can produce commercial value without altering the drug formulation, although a change to the primary container may require regulatory comparability work.

Portfolio expansion

Octocaine 100 can be used as an anchor product for a broader dental anesthetic portfolio:

Product concept	Commercial purpose
Lidocaine 2% with epinephrine 1:50,000	Greater vasoconstrictor concentration for selected procedures
Lidocaine 2% without epinephrine	Patients for whom vasoconstrictor use is undesirable
Articaine 4% with epinephrine	Competes in infiltration and routine dental anesthesia
Mepivacaine 3% plain	Vasoconstrictor-free alternative
Prilocaine with felypressin or other vasoconstrictor	Geographic portfolio expansion
Buffered local anesthetic	Injection-comfort differentiation
Sulfite-reduced epinephrine formulation	Hypersensitivity-focused positioning

A portfolio approach reduces dependence on one mature formulation and allows dental distributors to consolidate purchasing.

What regulatory issues affect an Octocaine 100 reformulation?

In the United States, lidocaine and epinephrine dental injections are regulated as prescription drug products. A formulation change may require a supplement, a new drug application strategy, an abbreviated pathway, or another FDA-supported regulatory route depending on the reference product, change scope, and approval status.[2]

The key regulatory workstreams include:

1. Excipient qualification and safety justification.
2. Comparative stability under ICH conditions.
3. Epinephrine degradation-product characterization.
4. Container-closure integrity.
5. Sterility validation.
6. Particulate and visible-inspection controls.
7. Extractables and leachables assessment.
8. Dose-delivery testing through dental syringes.
9. In-use and simulated-use studies.
10. Labeling review for sulfite, latex, single-dose, and storage statements.

Sulfite removal can be commercially attractive, but it may eliminate a known stabilizer and therefore increase the burden of long-term stability evidence. A reformulated product cannot rely on the stability profile of the original Octocaine 100 formulation.

What patents protect Octocaine 100 and its excipient strategy?

The active-ingredient combination is technologically mature. The most defensible intellectual-property opportunities are more likely to involve:

• Specific low-sulfite compositions
• Stabilized epinephrine formulations
• Buffered local anesthetic systems
• Dual-chamber or point-of-use mixing cartridges
• Oxygen-control filling methods
• Cartridge materials and closure systems
• Manufacturing processes that reduce oxidation impurities
• Specific impurity limits or stability profiles
• Combination drug-device delivery systems

A conventional lidocaine hydrochloride 2% and epinephrine 1:100,000 formulation is unlikely to support broad composition-of-matter exclusivity because the combination has long been used in dentistry. Patent value would depend on claim scope, enablement, prior art, prosecution history, and whether the claims cover a commercially necessary product configuration.

Patent diligence should cover U.S. Patent and Trademark Office records, FDA Orange Book listings, international patent families, and litigation databases. No reliable patent number, expiration date, Orange Book listing, Paragraph IV challenge, settlement agreement, or active litigation position should be assigned to Octocaine 100 without product-specific verification in current regulatory and patent records.

How strong is the commercial patent estate for Octocaine 100?

The likely patent position is weaker for the legacy formulation and stronger for a genuinely differentiated reformulation or delivery system.

Asset	Likely protection profile
Lidocaine active ingredient	Mature, limited standalone exclusivity
Epinephrine active ingredient	Mature, limited standalone exclusivity
Standard 1:100,000 combination	Likely crowded prior-art field
Sodium metabisulfite stabilization	Potentially difficult to protect broadly
Sulfite-free stabilization	More meaningful formulation opportunity
Buffered ready-to-use formulation	Potential formulation and method claims
Dual-chamber cartridge	Device and combination-product claims
Oxygen-controlled manufacturing	Process claims, dependent on novelty
Cartridge closure system	Device, packaging, or combination claims

A formulation patent should be drafted around measurable technical advantages, such as improved epinephrine retention, reduced oxidation impurities, specified oxygen levels, defined pH ranges, or improved in-use stability. Functional claims without adequate examples may face enablement and written-description challenges.

What generic entry risks exist for Octocaine 100?

Generic entry risk is high for a conventional lidocaine-epinephrine dental injection because the active ingredients, route, dosage form, and clinical use are established. Competition is likely to focus on manufacturing cost, sterile capacity, cartridge availability, distributor relationships, and regulatory execution.

The principal barriers are operational rather than discovery-based:

• Reliable sterile cartridge filling
• Consistent epinephrine potency
• Low particulate counts
• Container-closure integrity
• Stable supply of dental cartridges
• Compliance with current good manufacturing practice
• Product-specific regulatory approval
• Distributor access

Paragraph IV litigation risk would be relevant only if an approved reference product has Orange Book-listed patents that a generic applicant must address. Method-of-use patents generally provide less practical protection against ordinary generic substitution unless they are listed and enforceable in a manner that affects the applicable regulatory filing.

Biosimilar risk is not relevant to Octocaine 100 because lidocaine and epinephrine are small-molecule active ingredients, not biologics. The relevant competitive threat is generic substitution and formulation-based differentiation.

How does Octocaine 100 compare with competing dental anesthetics?

Product type	Main advantage	Main limitation	Excipient opportunity
Lidocaine 2% with epinephrine 1:100,000	Familiar, established clinical profile	Sulfite exposure and mature pricing	Sulfite reduction, buffering
Lidocaine 2% plain	No epinephrine	Shorter duration and greater bleeding risk	Comfort and stability optimization
Articaine 4% with epinephrine	Strong dental adoption in many markets	Different active-ingredient profile	Cartridge and injection-comfort improvements
Mepivacaine 3% plain	Vasoconstrictor-free option	Duration and hemostasis limitations	Preservative-free positioning
Prilocaine-based products	Alternative pharmacology	Methemoglobinemia considerations	Safer excipient and dosing presentation

Octocaine 100 competes primarily on familiarity, availability, price, and practice workflow. A new entrant should not rely on the active ingredients alone. It needs a measurable product advantage.

Key Takeaways

• Octocaine 100 is a lidocaine hydrochloride 2% and epinephrine 1:100,000 dental injection.
• Sodium metabisulfite is central to epinephrine stability but creates a sulfite-sensitivity positioning issue.
• The strongest formulation opportunity is a reduced-sulfite or sulfite-free product supported by oxygen, pH, packaging, and impurity controls.
• Buffering could improve injection comfort but creates a direct stability tradeoff for epinephrine.
• Packaging, cartridge compatibility, and sterile supply reliability may provide more practical differentiation than the base formulation.
• Generic competition is likely to be strong for the conventional product.
• Biosimilar risk does not apply.
• Patent value is more likely to arise from a novel stabilization system, cartridge, device, or manufacturing process than from the mature active-ingredient combination.
• Commercial success would depend on regulatory execution, dental-distributor access, supply continuity, and a clear clinical or workflow benefit.

FAQs

Is Octocaine 100 sulfite-free?

No. Octocaine 100 formulations generally use sodium metabisulfite to stabilize epinephrine. Product-specific labeling should control for the relevant market and presentation.[1]

Can sodium metabisulfite be removed from Octocaine 100?

It can be investigated, but removal requires a replacement stability strategy. Oxygen control, packaging, pH optimization, metal control, and alternative antioxidants may be needed to maintain epinephrine potency.

Does Octocaine 100 contain a preservative?

Sodium metabisulfite functions primarily as an antioxidant for epinephrine rather than as a conventional antimicrobial preservative. The product should not be described as sulfite-free merely because it lacks an antimicrobial preservative.

Is a buffered Octocaine 100 product commercially viable?

Yes, but the product would need to demonstrate acceptable epinephrine stability, sterility, pH control, injection performance, and cartridge compatibility. A ready-to-use buffered product would have greater convenience value than a chairside mixing process.

Can a new Octocaine 100 formulation receive patent protection?

Potentially. The strongest candidates are narrow claims covering a defined stabilization system, low-sulfite composition, buffered formulation, cartridge architecture, oxygen-control process, or demonstrated stability advantage.

References

1. DailyMed. (n.d.). Octocaine-100: Lidocaine hydrochloride and epinephrine injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/

4. U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/